Taylor J Moon
Overview
Explore the profile of Taylor J Moon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi A, Moon T, Bhalotia A, Rajan A, Ogunnaike L, Hutchinson D, et al.
Mol Pharm
. 2025 Mar;
PMID: 40035231
The engineerability of lipid nanoparticles (LNPs) and their ability to deliver nucleic acids make LNPs attractive tools for cancer immunotherapy. LNP-based gene delivery can be employed for various approaches in...
2.
Moon T, Ta H, Bhalotia A, Paulsen K, Hutchinson D, Arkema G, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39209454
Background: Immune checkpoint protein V-domain immunoglobulin suppressor of T cell activation (VISTA) controls antitumor immunity and is a valuable target for cancer immunotherapy. Previous mechanistic studies have indicated that VISTA...
3.
Choi A, Moon T, Abuhashim W, Bhalotia A, Qian H, Paulsen K, et al.
J Control Release
. 2023 Apr;
362:812-819.
PMID: 37011838
Targeting ligands have been widely used to increase the intratumoral accumulation of nanoparticles and their uptake by cancer cells. However, these ligands aim at targets that are often also upregulated...
4.
Atukorale P, Moon T, Bokatch A, Lusi C, Routhier J, Deng V, et al.
Nanoscale
. 2022 Jan;
14(4):1144-1159.
PMID: 35023530
Lethal cancer is characterized by drug-resistant relapse and metastasis. Here, we evaluate the efficacy of a neoadjuvant therapeutic strategy prior to surgery that combines the immune checkpoint inhibitor anti-PD1 with...
5.
Covarrubias G, Moon T, Loutrianakis G, Sims H, Umapathy M, Lorkowski M, et al.
J Mater Chem B
. 2021 Nov;
10(2):224-235.
PMID: 34846443
To alter the immunosuppressive tumor microenvironment (TME), we developed an immunostimulatory nanoparticle (NP) to reprogram a tumor's dysfunctional and inhibitory antigen-presenting cells (APCs) into properly activated APCs that stimulate tumor-reactive...
6.
Covarrubias G, Lorkowski M, Sims H, Loutrianakis G, Rahmy A, Cha A, et al.
Nanoscale Adv
. 2021 Nov;
3(20):5890-5899.
PMID: 34746645
Iron oxide nanoparticles (IONPs) have often been investigated for tumor hyperthermia. IONPs act as heating foci in the presence of an alternating magnetic field (AMF). It has been shown that...
7.
Becicka W, Bielecki P, Lorkowski M, Moon T, Zhang Y, Atukorale P, et al.
Nanoscale Adv
. 2021 Sep;
3(17):4961-4972.
PMID: 34485818
The efficacy of immunotherapies is often limited by the immunosuppressive tumor microenvironment, which is populated with dysfunctional innate immune cells. To reprogram the tumor-resident innate immune cells, we developed immunostimulatory...
8.
Bielecki P, Lorkowski M, Becicka W, Atukorale P, Moon T, Zhang Y, et al.
Nanoscale Horiz
. 2021 Jan;
6(2):156-167.
PMID: 33400743
The high mortality associated with glioblastoma multiforme (GBM) is attributed to its invasive nature, hypoxic core, resistant cell subpopulations and a highly immunosuppressive tumor microenvironment (TME). To support adaptive immune...
9.
Moon T, Elliott M
Methods Mol Biol
. 2019 Oct;
2041:345-349.
PMID: 31646502
Extracellular nucleotides are potent damage-associated molecular patterns that shape the immune response to cell stress and tissue damage. These nucleotides are sensed by purinergic receptors and mediate a wide range...
10.
Atukorale P, Raghunathan S, Raguveer V, Moon T, Zheng C, Bielecki P, et al.
Cancer Res
. 2019 Aug;
79(20):5394-5406.
PMID: 31431457
Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerful antitumor immune...